Montelukast Teva (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is indicated for the management of asthma and allergic rhinitis in adults and children. GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Teva belongs to the leukotriene‑modifier class and is used to control inflammatory airway diseases. - Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes associated with seasonal allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate discomfort. - Abdominal pain: occasional stomach discomfort. - Cough: transient irritation of the throat. - Nausea: occasional feeling of queasiness. - Dizziness: brief episodes of light‑headedness. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue that may impair breathing. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Severe rash: including Stevens‑Johnson syndrome. - Hepatic injury: abnormal liver function tests. - Anaphylaxis: rare, life‑threatening allergic reaction.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Assess asthma control: ensure baseline therapy is optimized. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Use caution in hepatic impairment: adjust therapy if liver disease is present. - Avoid in patients with known hypersensitivity to montelukast or any excipients. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Montelukast can interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may markedly reduce montelukast exposure. - Carbamazepine: may lower montelukast levels, reducing efficacy.

Moderate Interactions (Monitor Closely): - Fluconazole: can raise montelukast concentrations modestly. - Warfarin: monitor INR as montelukast may affect anticoagulation. - Theophylline: observe for additive bronchodilator effects.